FCCC LOGO Faculty Publications
Witzig TE , White CA , Wiseman GA , Gordon LI , Emmanouilides C , Raubitschek A , Janakiraman N , Gutheil J , Schilder RJ , Spies S , Silverman DHS , Parker E , Grillo-Lopez AJ
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
Journal of Clinical Oncology. 1999 Dec;17(12) :3793-3803
PMID: ISI:000084043300012   
Back to previous list
Purpose: Yttrium-90 ibritumomab tiuxetan (IDEC-Y2B8) is a murine immunoglobulin G1 kappa monoclonal antibody that covalently binds MX-DTPA (tiuxetan), which chelates the radioisotope yttrium-90. The antibody targets CD20, a B- lymphocyte antigen. A multicenter phase I/II trial was conducted to compare two doses of unlabeled rituximab given before radiolabeled antibody, to determine the maximum- tolerated single dose of IDEC-Y2B8 that could be administered without stem-cell support, and to evaluate safety and efficacy. Patients and Methods: Eligible patients had relapsed or refractory (two prior regimens or anthracycline if low-grade disease) CD20(+) B-cell low-grade, intermediate-grade, or mantle-cell non-Hodgkin's lymphoma (NHL), There was no limit on bulky disease, and 59% had at least one mass greater than or equal to 5 cm. Results: The maximum-tolerated dose was 0.4 mCi/kg IDEC-Y2B8 (0.3 mCi/kg for patients with baseline platelet counts 100 to 149,000/mu L). The overall response rate for the intent-to-treat population (n = 51) was 67% (26% complete response [CR]; 41% partial response [PR]); for low- grade disease (n = 34), 82% (26% CR; 56% PR); for intermediate- grade disease (n = 14), 43%; and for mantle-cell disease (n = 3), 0%. Responses occurred in patients with bulky disease (greater than or equal to 7 cm; 41%) and splenomegaly (50%). Kaplan-Meier estimate of time ta disease progression in responders and duration of response is 12.9+ months and 11.7+ months, respectively Adverse events were primarily hematologic and correlated with baseline extent of marrow involvement with NHL and baseline platelet count. One patient (2%) developed an anti-antibody response (human antichimeric antibody/human antimouse antibody). Conclusion: These phase I/II data demonstrate that IDEC-Y2B8 radioimmunotherapy is a safe and effective alternative for outpatient therapy of patients with relapsed or refractory NHL. A phase III study is ongoing. J Clin Oncol 17:3793-3803. (C) 1999 by American Society of Clinical Oncology.
Times Cited: 95 English Article 262AJ J CLIN ONCOL